Oliviero Toscani and his battle against amyloidosis. Oliviero Toscani, a well-known Italian photographer and artist, was ...

Trientine hydrochloride is under clinical development by Innolife and currently in Phase I for Amyloidosis. According to GlobalData, Phase I drugs for Amyloidosis have a 91% phase transition success ...

Medically reviewed by Anita C. Chandrasekaran, MD Hereditary transthyretin (hATTR) amyloidosis is a rare progressive disease ...

Intellia Therapeutics prioritizes late-stage gene-editing programs for HAE and ATTR amyloidosis in 2025, announces leadership ...

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on ...

Immix Biopharma (IMMX) announced completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study of NXC-201, an ...

About NXC-201 NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated high complete ...

Multiple myeloma and AL amyloidosis are conditions linked to plasma cells in the bone marrow. Multiple myeloma (MM) is a cancer affecting the plasma cells, which are mostly in the bone marrow.

Several case reports and retrospective cohort studies have described a marginal benefit with the use of internal cardioverter defibrillators in patients with cardiac amyloidosis. Detection of ...

Tolcapone is under clinical development by Corino Therapeutics and currently in Phase II for Amyloidosis. According to GlobalData, Phase II drugs for Amyloidosis have a 72% phase transition success ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...